Challenges and opportunities for siRNA-based cancer treatment

被引：81

作者：

Wang, Tao ^{[1
]}

Shigdar, Sarah ^{[2
]}

Al Shamaileh, Hadi ^{[2
]}

Gantier, Michael P. ^{[3
,4
]}

Yin, Wang ^{[2
]}

Xiang, Dongxi ^{[2
]}

Wang, Lan ^{[1
]}

Zhou, Shu-Feng ^{[5
]}

Hou, Yingchun ^{[6
]}

Wang, Peng ^{[1
]}

Zhang, Weihong ^{[1
]}

Pu, Chunwen ^{[7
]}

Duan, Wei ^{[2
]}

机构：

[1] Zhengzhou Univ, Sch Nursing, Zhengzhou 450001, Peoples R China

[2] Deakin Univ, Sch Med, 75 Pigdons Rd, Victoria 3217, Australia

[3] Hudson Inst Med Res, Ctr Canc Res, Clayton, Vic 3168, Australia

[4] Monash Univ, Dept Mol & Translat Sci, Clayton, Vic 3168, Australia

[5] Univ S Florida, Dept Pharmaceut Sci, Coll Pharm, Tampa, FL 33612 USA

[6] Shaanxi Normal Univ, Sch Life Sci, Dept Cell Biol, Xian 710119, Shaanxi, Peoples R China

[7] Dalian Sixth Peoples Hosp, Dalian 116033, Liaoning Provin, Peoples R China

来源：

CANCER LETTERS | 2017年 / 387卷

关键词：

RNA interference; Tumour; Nanoparticle; EPR effect; Endosome escape; Off-target; IN-VIVO; MODIFIED OLIGONUCLEOTIDES; SYSTEMIC DELIVERY; TARGETED THERAPY; RNA INTERFERENCE; DRUG-DELIVERY; NANOPARTICLES; DESIGN; POTENCY; THERAPEUTICS;

D O I：

10.1016/j.canlet.2016.03.045

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As one of the life-threatening diseases involving multi-step genetic and epigenetic disorders, cancer has long been a dynamic research area for siRNA-based therapy as half of the current siRNA-based clinical trials are involved in oncology. However, despite consistent enthusiasm in the academic world, siRNA-based cancer treatment still faces obstacles and difficulties in clinical development. In this article, we discuss key challenges facing siRNA-based cancer treatment revealed from recent clinical and preclinical studies, including chemical modification, tumour penetration, endosomal escape, target selection and off-target effects. In addition, opportunities and avenues for translating siRNA technology from bench to oncologic clinics are explored. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：77 / 83

页数：7

共 50 条

[1] Opportunities and challenges of siRNA-based therapies
Kohlbrenner, W. E.
[J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2006, 161 (03) : 200 - 201
[2] Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment
Hattab, Dima
Gazzali, Amirah Mohd
Bakhtiar, Athirah
[J]. PHARMACEUTICS, 2021, 13 (07)
[3] siRNA-based approaches in cancer therapy
Devi, G. R.
[J]. CANCER GENE THERAPY, 2006, 13 (09) : 819 - 829
[4] siRNA-based approaches in cancer therapy
G R Devi
[J]. Cancer Gene Therapy, 2006, 13 : 819 - 829
[5] SiRNA-based approaches to pancreatic cancer
Ocker, M
Neureiter, D
Lüders, M
Zopf, S
Ganslmayer, M
Hahn, EG
Schuppan, D
Herold, C
[J]. GASTROENTEROLOGY, 2005, 128 (04) : A437 - A437
[6] Advances in the development of siRNA-based therapeutics for cancer
Shen, Yu
[J]. IDRUGS, 2008, 11 (08) : 572 - 578
[7] siRNA-based nanomedicine
Zhao, Jing
Mi, Yu
Feng, Si-Shen
[J]. NANOMEDICINE, 2013, 8 (06) : 859 - 862
[8] Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases
Mishra, Neeraj
Ashique, Sumel
Garg, Ashish
Rai, Vineet Kumar
Dua, Kamal
Goyal, Amit
Bhatt, Shvetank
[J]. DRUG DISCOVERY TODAY, 2022, 27 (05) : 1431 - 1440
[9] Development of siRNA-based therapeutics
Polisky, Barry
[J]. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2004, 40 : 2A - 2A
[10] Targeting glucose uptake with siRNA-based nanomedicine for cancer therapy
Xu, Cong-Fei
Liu, Yang
Shen, Song
Zhu, Yan-Hua
Wang, Jun
[J]. BIOMATERIALS, 2015, 51 : 1 - 11

← 1 2 3 4 5 →